RxDoctor Payments Data

Han Kim, MD

Cardiovascular Disease · Durham, NCNPI 1730292855

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 9 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by Siemens Medical Solutions USA, Inc. at 49.0% of the total. Reporting peaked in 2019 at $228 and has fallen 81.2% since, to $43 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in NC, where the typical reported total is $1,959.

$548in general payments, 2019–2025

Across 9 payments — averaging $60.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Siemens Medical Solutions USA, Inc.$268
  • Boston Scientific$166
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$101
  • Medtronic$12
$194,708in research payments, 2019–2025

Across 7 payments — averaging $27,815 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Astellas Pharma Global Development$114K
  • Guerbet LLC$80K
  • Siemens Medical Solutions USA, Inc.$842

What the payments were for

  • Food & beverage$548100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$548 in reported general payments places this provider in the 25th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina →

Medicare billing

Part B allowed, 2024
$34,853
Medicare patients
219
Services billed
563

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin22$33,655
Repatha SureclickEvolocumab32$25,440
Rosuvastatin Calcium36$384
Metoprolol Succinate18$305
Ezetimibe16$174
Losartan Potassium20$151

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Durham

See the full list for North Carolina →

Where these figures come from

Is this you, or does something look wrong? →